Moderna President Stephen Hoge said there is a risk that existing COVID-19 shots may struggle in their effectiveness against the Omicron variant, though it’s too early to say by how much. Hoge’s comments follow those of Moderna’s Chief Executive Officer Stéphane Bancel, who said last week that he predicts current vaccines will be far less effective against the latest CCP (Chinese Communist Party) virus variant due to the high number of mutations on the spike protein. “It seems likely that the Omicron variant is going to make a dent in our vaccine’s efficacy—in fact, in all vaccines’ efficacy,” the president of the U.S.-based pharmaceutical company said during an interview with CNN. “The things that lead us to believe that are our prior experiences, including with the Delta variant … [which] had an impact on vaccines’ efficacy,” he added. It is unclear how big the decrease in the shots’ efficacy will be, Hoge said, noting …